TECH · BIO-TECHNE Corp
$71.60
-0.17 (-0.24%)
At close · Jul 24
Market Cap
$11.21B
Shares
156.57M
BIO-TECHNE Corp Earnings Call Transcripts
Every quarterly earnings call for BIO-TECHNE Corp (TECH) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲11.3%
$288.23M
$61.52M
'22 Q4
22-08-04
▲4.6%
$269.65M
$89.56M
'23 Q1
22-11-01
▲0.9%
$271.58M
$50.01M
'23 Q2
23-02-02
▲1.3%
$294.15M
$70.22M
'23 Q3
23-05-03
▲4.5%
$301.32M
$75.48M
'23 Q4
23-08-08
▲2.7%
$276.94M
$50.99M
'24 Q1
23-10-31
▲0.4%
$272.60M
$27.46M
'24 Q2
24-02-01
▲3.2%
$303.43M
$49.06M
'24 Q3
24-05-01
▲1.6%
$306.10M
$40.59M
'24 Q4
24-08-07
▲4.5%
$289.46M
$33.60M
'25 Q1
24-10-30
▲9%
$297.03M
$34.89M
'25 Q2
25-02-05
▲4.2%
$316.18M
$22.59M
'25 Q3
25-05-07
▲3.5%
$316.96M
−$17.68M
'25 Q4
25-08-06
▼1%
$286.56M
$38.19M
'26 Q1
25-11-05
▼0.4%
$295.88M
$38.01M
'26 Q2
26-02-04
LATEST
▼1.5%
$311.42M
$51.05M
'26 Q3
26-05-06
Earnings call
FY26 · Q3
2026-05-06
BIO-TECHNE Corp Q3 FY2026 Earnings Call
Positive tone
Cell therapy and GMP proteins
Spatial biology and Comet platform
China and Asia end market
Revenue
$311.42M
▼ 1.5% YoY Diluted EPS
$0.32
▲ 128.6% YoY Gross margin
66.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-02-04
BIO-TECHNE Corp Q2 FY2026 Earnings Call
Positive tone
Cell therapy and Fast Track headwind
Strategic growth verticals
Margin expansion and operating leverage
Revenue
$295.88M
▼ 0.4% YoY Diluted EPS
$0.24
▲ 9.1% YoY Gross margin
64.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2025-11-05
BIO-TECHNE Corp Q1 FY2026 Earnings Call
Positive tone
Cell therapy clinical stage timing / Wilson Wolf
Academic end market stabilization
Spatial biology and China growth
Revenue
$286.56M
▼ 1% YoY Diluted EPS
$0.24
▲ 14.3% YoY Gross margin
65.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2025-08-06
BIO-TECHNE Corp Q4 FY2025 Earnings Call
Positive tone
Cell and gene therapy franchise
China geographic performance
Policy and tariff uncertainty
Revenue
$316.96M*
▲ 3.5% YoY Gross margin
62.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-05-07
BIO-TECHNE Corp Q3 FY2025 Earnings Call
Positive tone
Pharma/biopharma end market recovery
Tariffs and macro uncertainty
NIH funding and US academic end-market uncertainty
Revenue
$316.18M
▲ 4.2% YoY Diluted EPS
$0.14
▼ 54.8% YoY Gross margin
67.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-02-05
BIO-TECHNE Corp Q2 FY2025 Earnings Call
Confident tone
China geographic headwind and outlook
Spatial biology and multi-omic capabilities
Cell therapy and GMP reagents
Revenue
$297.03M
▲ 9% YoY Diluted EPS
$0.22
▲ 29.4% YoY Gross margin
65.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2024-10-30
BIO-TECHNE Corp Q1 FY2025 Earnings Call
Positive tone
Biopharma end-market stabilization
Cell and gene therapy / GMP reagents
Spatial biology and molecular diagnostics
Revenue
$289.46M
▲ 4.5% YoY Diluted EPS
$0.21
▼ 32.3% YoY Gross margin
63.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2024-08-07
BIO-TECHNE Corp Q4 FY2024 Earnings Call
Positive tone
ProteinSimple / instrumentation franchise
End market stabilization and recovery
Growth verticals outperformance
Revenue
$306.10M*
▲ 1.6% YoY Gross margin
66.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-05-01
BIO-TECHNE Corp Q3 FY2024 Earnings Call
Confident tone
China end market stabilization
Spatial biology / Comet instrument
Biopharma / biotech funding environment
Revenue
$303.43M
▲ 3.2% YoY Diluted EPS
$0.31
▼ 27.9% YoY Gross margin
67.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-02-01
BIO-TECHNE Corp Q2 FY2024 Earnings Call
Positive tone
China softness and stabilization
Lunaphore acquisition and M&A pipeline
CEO leadership transition
Revenue
$272.60M
▲ 0.4% YoY Diluted EPS
$0.17
▼ 45.2% YoY Gross margin
64.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2023-10-31
BIO-TECHNE Corp Q1 FY2024 Earnings Call
Revenue
$276.94M
▲ 2.7% YoY Diluted EPS
$0.31
▼ 43.6% YoY Gross margin
66.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2023-08-08
BIO-TECHNE Corp Q4 FY2023 Earnings Call
Revenue
$301.32M*
▲ 4.5% YoY Gross margin
67.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-05-03
BIO-TECHNE Corp Q3 FY2023 Earnings Call
Revenue
$294.15M
▲ 1.3% YoY Diluted EPS
$0.43
▲ 16.2% YoY Gross margin
68.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-02-02
BIO-TECHNE Corp Q2 FY2023 Earnings Call
Revenue
$271.58M
▲ 0.9% YoY Diluted EPS
$0.31
▼ 36.7% YoY Gross margin
67.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2022-11-01
BIO-TECHNE Corp Q1 FY2023 Earnings Call
Revenue
$269.65M
▲ 4.6% YoY Diluted EPS
$0.55
▲ 30.2% YoY Gross margin
66.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2022-08-04
BIO-TECHNE Corp Q4 FY2022 Earnings Call
Revenue
$288.23M*
▲ 11.3% YoY Gross margin
69.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-05-04
BIO-TECHNE Corp Q3 FY2022 Earnings Call
Revenue
$290.38M
▲ 19.2% YoY Diluted EPS
$0.37
▲ 32.1% YoY Gross margin
69.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-02-01
BIO-TECHNE Corp Q2 FY2022 Earnings Call
Revenue
$269.28M
▲ 20.1% YoY Diluted EPS
$0.49
▲ 70.4% YoY Gross margin
68.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2021-11-02
BIO-TECHNE Corp Q1 FY2022 Earnings Call
Revenue
$257.72M
▲ 26.2% YoY Diluted EPS
$0.42
▲ 103.6% YoY Gross margin
66.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2021-08-05
BIO-TECHNE Corp Q4 FY2021 Earnings Call
Revenue
$259.03M*
▲ 47.3% YoY Gross margin
67.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-05-06
BIO-TECHNE Corp Q3 FY2021 Earnings Call
Revenue
$243.55M
▲ 25.1% YoY Diluted EPS
$0.28
▲ 21.7% YoY Gross margin
69.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-02-02
BIO-TECHNE Corp Q2 FY2021 Earnings Call
Revenue
$224.25M
▲ 21.3% YoY Diluted EPS
$0.29
▼ 61.9% YoY Gross margin
67.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2020-11-05
BIO-TECHNE Corp Q1 FY2021 Earnings Call
Revenue
$204.20M
▲ 11.4% YoY Diluted EPS
$0.21
▲ 124.3% YoY Gross margin
67.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2020-08-04
BIO-TECHNE Corp Q4 FY2020 Earnings Call
Revenue
$175.83M
▼ 8.3% YoY Diluted EPS
$0.37
▲ 252.4% YoY Gross margin
64.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-04-30
BIO-TECHNE Corp Q3 FY2020 Earnings Call
Revenue
$194.68M
▲ 5.3% YoY Diluted EPS
$0.23
▼ 20% YoY Gross margin
66.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-02-04
BIO-TECHNE Corp Q2 FY2020 Earnings Call
Revenue
$184.93M
▲ 6% YoY Diluted EPS
$0.76
▲ 571.1% YoY Gross margin
65.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2019-09-30
BIO-TECHNE Corp Q1 FY2020 Earnings Call
Revenue
$183.24M
▲ 12.4% YoY Diluted EPS
$0.09
▼ 17.8% YoY Gross margin
64.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–27 of 27 earnings calls
Key facts
CIK
842023
CUSIP
09073M104
13F (30d)
118 filings
118 filers
Visit website
Investor relations